News
Market and company headlines
TLRYAll
Loading
07:00Oct 221 Story
07:00Oct 211 Story
12:00Oct 191 Story
18:00Oct 151 Story
03:00-08:00Oct 132 Stories
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
INFARMED approval authorizes Tilray Medical’s Cantanhede, Portugal facility to conduct microbiological and chemical/physical testing on-site, advancing pharmaceutical-grade quality control within its EU-GMP production platformCANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulat
Tilray Brands’ Unit Tilray Medical Secures Key Regulatory Approval For In-House Testing At Portugal Facility
Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), today announced a key
14:00-22:00Oct 122 Stories
BrewDog Acquisition Boosts Tilray's Q1 Performance
Tilray (TLRY) Q1-2027 results: BrewDog revenue rose, cannabis sales fell, losses and negative FCF persist. Read here for a detailed analysis.
3 Huge Red Flags From Tilray's Q1 Earnings Report
The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.
12:00Oct 121 Story
14:00-18:00Oct 102 Stories
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.
3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices
Tilray's stock isn't the bargain it appears to be at first.
10:00Oct 91 Story
16:00-23:00Oct 82 Stories
11:00-13:00Oct 82 Stories
Tilray Brands Q1 Earnings Call Highlights
Tilray Brands (NASDAQ:TLRY) reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million. Net revenue rose 23%
Following Tilray Earnings, Here's What Comes Next for TLRY Stock
Tilray reports record revenue for its fiscal Q1. Options sentiment suggests TLRY shares will rip higher through the end of next week.
10:00Oct 82 Stories
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease
Tilray Brands just posted a first-quarter revenue record, yet investors are selling the stock hard this morning. The reason hiding inside the headline number explains why Canopy Growth and Aurora Cannabis are watching from a safe distance.
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call Transcript
Tilray Brands, Inc. (TLRY) Q1 2027 Earnings Call October 8, 2026 8:30 AM EDTCompany ParticipantsBerrin Noorata - Chief Corporate Affairs OfficerIrwin Simon...
05:00-10:00Oct 82 Stories
Tilray revenue rises as beverage business drives record quarterly sales
Tilray Inc (NASDAQ:TLRY), the cannabis and consumer products company, reported record first-quarter revenue of $257.1 million, up 23% from a year earlier, driven by strong growth in beverages and international markets. Gross profit rose 35% to $77.5 million, while gross margin expanded to...
Tilray Brands Q1 2027 Earnings Call Transcript
Tilray Brands (NASDAQ:TLRY) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
03:00Oct 82 Stories
Tilray Brands Q1 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $257.147M Miss $267.813M Estimate
Tilray Brands (NASDAQ:TLRY) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.20) by 90 percent. The company reported quarterly sales of $257.147 million which missed the
Tilray Brands Q1 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $257.147M Miss $267.464M Estimate
Tilray Brands (TSX:TLRY) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.20) by 90 percent. The company reported quarterly sales of $257.147 million which missed the
